Facebook
Twitter
LinkedIn
ForwardNCCN 2023 Breast Cancer Congress with Updates from the 2022 San Antonio Breast Cancer Symposium
This program will provide expert insights on the current recommendations of care for patients with breast cancer and include the latest clinical research updates to assist clinicians in formulating breast cancer management strategies.
Target Audience
This educational program is designed to meet the educational needs of physicians, nurse practitioners, nurses, PAs, pharmacists, and other health care professionals who manage patients with breast cancer.
Learning Objectives
The ultimate goal for NCCN continuing education is to change patient outcomes by improving the competence and performance of clinicians. The goal of the NCCN 2023 Breast Cancer Congress with Updates from the 2022 San Antonio Breast Cancer Symposium is to ensure that members of the interprofessional oncology care team have the knowledge and skills necessary to:
- Summarize the current standards of oncology care, key updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), and clinical research updates from the 2022 San Antonio Breast Cancer Symposium (SABCS), and integrate appropriate strategies into clinical practice to optimize the management of patients with breast cancer.
- Evaluate new, emerging and novel therapeutic agents, advances in care, and clinical trials data and apply relevant findings into the management of patients with breast cancer.
Click here to view the learning objectives for each individual session.
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Faculty Disclosures
The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.
Nina Bickell, MD, MPH
Harold J. Burstein, MD, PhD
Meena S. Moran, MD
Tara Sanft, MD
Jessica S. Young, MD
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Chau T. Dang, MD
Daiichi-Sankyo Co.: Consulting Fee
Gilead Sciences, Inc.: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
Pfizer Inc.: Consulting Fee
Puma Biotechnology: Grant/Research Support
Roche/Genentech: Consulting Fee; Grant/Research Support
SeaGen: Consulting Fee
Anthony D. Elias, MD
Astellas Pharma US, Inc.: Grant/Research Support
BioAtla Inc.: Grant/Research Support
C4 Therapeutics, Inc.: Grant/Research Support
Epizyme: Grant/Research Support
Fosun Orinove Pharma Tech, Inc: Grant/Research Support
ImmuneOnco Biopharmaceuticals Co., Ltd: Grant/Research Support
Infinity Pharmaceuticals, Inc.: Grant/Research Support
PTC Therapeutics: Grant/Research Support
Quantum Leap Health Consortium: Grant/Research Support
Zenshine Pharmaceuticals: Grant/Research Support
William J. Gradishar, MD
AstraZeneca Pharmaceuticals LP: Honoraria; Scientific Advisor
Biotheronostics: Honoraria; Scientific Advisor
Daiichi-Sankyo co.: Honoraria; Scientific Advisor
Eli Lilly and Company: Scientific Advisor
ImmunoGen, Inc.: Honoraria; Scientific Advisor
MacroGenics: Scientific Advisor
Puma Biotechnology: Scientific Advisor
Seattle Genetics, Inc.: Scientific Advisor
Rachel C. Jankowitz, MD
Biotheranostics: Scientific Advisor
Ami Shah, MD
AstraZeneca Pharmaceuticals LP: Honoraria
Gilead Sciences, Inc.: Honoraria
Hatem Soliman, MD
Amgen Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Consulting Fee
Merck & Co., Inc.: Product/Speakers Bureau
Novartis Pharmaceuticals Corporation: Consulting Fee
Puma Biotechnology: Consulting Fee
SeaGen: Consulting Fee
NCCN Staff Disclosures
None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates this educational activity for a maximum of 5.75 contact hours. This program offers 3 pharmacotherapeutic contact hours for nurses.
Pharmacists
NCCN designates this knowledge-based continuing education activity for 5.75 contact hours (0.575 CEUs) of continuing education credit. UAN: JA4008196-0000-23-013-L01-P
PAs
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 5.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
American Board of Internal Medicine Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.75 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Aggregated participant data will be shared with the commercial supporters of this activity.
American Board of Pathology Continuing Certification (CC)
This activity has been registered to offer credit in the American Board of Pathology’s (ABPath) Continuing Certification program. Successful completion of this CME activity enables the participant to earn up to 5.75 Lifelong Learning (Part II) credits.
Aggregated participant data will be shared with the commercial supporters of this activity.
American Board of Surgery Continuous Certification (CC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and/or Self-Assessment requirements of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.
American Board of Medical Specialties (MOC)
Through the American Board of Medical Specialties (“ABMS”) MOC Initiative to create a wide array of Maintenance of Certification (“MOC”) Activities through the ABMS MOC Directory, the NCCN 2023 Breast Cancer Congress has met the MOC requirements as a MOC Part II CME Activity (apply toward general CME requirement) by the following ABMS Member Boards:
MOC Part II CME Activity
Medical Genetics and Genomics
Pathology
Radiology
Available Credit
- 5.75 AAPA Category 1 CME credit
- 5.75 AMA PRA Category 1 Credit™
- 5.75 ANCC contact hours
- 3.00 ANCC Pharmacology Contact Hours
- 5.75 Participation
Price
Please log in with the email address you used for event registration.
Click the Take Course button to start the credit claiming process.
CE/MOC credit should be claimed for the congress as a whole, not session by session. You may claim credit for the congress only one time. When calculating your total credits, you should take into account all of the sessions you viewed either live or via recording. (Recordings and handouts are now available. Click the Take Course button to access them.)
Pharmacists: you must complete all requirements for credit by March 20, 2023.
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing